The maximum amount of Aranesp® that can be safely administered in single or multiple doses has not been determined. Doses over 3.0 mcg/kg/week for up to 28 weeks have been administered to CRF patients. Doses up to 8.0 mcg/kg every week and 15.0 mcg/kg every 3 weeks have been administered to cancer patients for up to 12-16 weeks. Excessive rise and rate of rise in hemoglobin concentration, however, have been associated with adverse events (see WARNINGS and DOSAGE AND ADMINISTRATION: Dose Adjustment). In the event of polycythemia, Aranesp® should be temporarily withheld (see DOSAGE AND ADMINISTRATION: Dose Adjustment). If clinically indicated, phlebotomy may be performed.